切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2021, Vol. 14 ›› Issue (02) : 184 -188. doi: 10.3877/cma.j.issn.1674-6902.2021.02.010

论著

S-腺苷甲硫氨酸抑制miR-34a依赖的肺癌转移的作用
彭小乐1, 郭东2, 林佳鹤3, 胡小强1, 靳凯悦1, 王建云1,()   
  1. 1. 101200 北京,首都医科大学附属北京友谊医院平谷医院心胸外科
    2. 101200 北京,北京安贞医院心外科
    3. 101200 北京,首都医科大学附属北京友谊医院平谷医院麻醉科
  • 收稿日期:2020-10-15 出版日期:2021-04-25
  • 通信作者: 王建云
  • 基金资助:
    北京市医院管理局"登峰"计划专项经费资助(DFL20180602)

Role of S-adenosylmethionine in suppressing mir-34a dependent lung cancer metastasis

Xiaole Peng1, Dong Guo2, Jiahe Lin3, Xiaoqiang Hu1, Kaiyue Jin1, Jianyun Wang1,()   

  1. 1. Department of Cardiothoracic Surgery, Pinggu Hospital, Beijing Friendship Hospital, Capital Medical University, Beijing 101200, China
    2. Department of Cardiac Surgery, Beijing Anzhen Hospital, Beijing 101200, China
    3. Department of Anesthesiology, Pinggu Hospital, Beijing Friendship Hospital, Capital Medical University, Beijing 101200, China
  • Received:2020-10-15 Published:2021-04-25
  • Corresponding author: Jianyun Wang
引用本文:

彭小乐, 郭东, 林佳鹤, 胡小强, 靳凯悦, 王建云. S-腺苷甲硫氨酸抑制miR-34a依赖的肺癌转移的作用[J]. 中华肺部疾病杂志(电子版), 2021, 14(02): 184-188.

Xiaole Peng, Dong Guo, Jiahe Lin, Xiaoqiang Hu, Kaiyue Jin, Jianyun Wang. Role of S-adenosylmethionine in suppressing mir-34a dependent lung cancer metastasis[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(02): 184-188.

目的

探讨S-腺苷甲硫氨酸抑制miRNA-34a依赖的肺癌转移机制。

方法

选取肺癌细胞A549,分别采用0、50、100、200、500 μM的S-腺苷甲硫氨酸(S-adenosylmethionine, SAMe)刺激A549细胞并检测miR-34a以及下游STAT3信号通路的表达情况,同时检测不同刺激条件下A549细胞的侵袭转移情况;实时荧光定量(real-time fluorescence quantification, qPCR)检测miR-34a、E-cadherin、α-catenin、N-cadherin、Vimentin的mRNA表达水平;Western Blot实验检测STAT3、p-STAT3、β-actin的表达水平;Transwell实验检测A549细胞的侵袭能力变化。

结果

随着SAMe浓度的增加,miR-34a的表达水平呈梯度增加,与对照组相比,经t检验分析,差异有统计学的意义(P<0.05);Western Blot实验显示,与对照组相比,500 μM SAMe刺激后,下游的p-STAT3蛋白水平下降,总STAT3和内参蛋白β-actin水平不变;qPCR结果显示,随着药物浓度的增加,表皮蛋白E-cadherin、α-catenin的mRNA水平上升,间质蛋白N-cadherin、Vimentin的mRNA水平下降;Transwell实验显示经50、100、200、500 μM的SAMe刺激后,A549细胞的侵袭转移抑制率分别为18.70%、31.24%、47.66%、58.46%,与对照组相比,经t检验分析,差异有统计学的意义(P<0.05)。

结论

SAMe可通过抑制miR-34a依赖的下游STAT3信号通路抑制肺癌细胞的侵袭转移,提示SAMe在肺癌侵袭转移过程中发挥重要作用。

Objective

To investigate the molecular mechanisms of S-adenosine methionine in suppressing lung cancer metastasis with a miRNA-34a-dependent manner.

Methods

A549 lung cancer cell was selected as the study model of this time research. A549 cells were stimulated with 0, 50, 100, 200, 500 μM SAMe, respectively and the expression of miR-34a and its related STAT3 signaling pathways were also detected. The invasive capacity of cells was detected under various condition as well; miR-34a, E-cadherin, α-catenin, N-cadherin and Vimentin mRNA expression were detected by qPCR method; Western Blot was used to detect expression of STAT3, p-STAT3 and β-actin; Invasive capacity of A549 cells was detected by Transwell experiment.

Results

As the increase of SAMe concentration, miR-34a expression increased gradually, and when it was compared to the control group, the difference was statistically significant through the t-test (P<0.05); Western Blot experiments showed that p-STAT3 protein level of 500 μM SAMe stimulation was lower than 0 μM treatment, while total STAT3 and β-actin level had no change; q-PCR results showed that E-cadherin and α-catenin level elevated, but N-cadherin and Vimentin level decreased as the increase of drug concentration; Transwell experiments showed that invasive inhibitory rates of A549 cells in 50, 100, 200, 500 μM of SAMe were 18.70%, 31.24%, 47.66% and 58.46%, respectively. And compared to the control group, the difference had statistical significance by t-tset (P<0.05).

Conclusion

SAMe could suppress cell metastasis through a miR-34a-dependent manner by inhibiting STAT3 signaling pathway in lung cancer cells, which suggested a potential role of SAMe in metastasis of lung cancer.

表1 Q-PCR引物序列
图1 SAMe诱导miR-34a的表达;注:*与对照组相比,差异有统计学意义,P<0.05
图2 SAMe处理后STAT3信号通路的变化
表2 蛋白灰度分析结果
图3 不同浓度SAMe处理A549细胞的侵袭抑制率;注:*与对照组相比,差异有统计学意义,P<0.05;**与对照组相比,差异有统计学意义,P<0.01
图4 SAMe抑制肺癌细胞的转移;注:A:0 μM SAMe处理;B:500 μMSAMe处理
图5 A549细胞表皮间质标志物变化;注:*与对照组相比,差异有统计学意义,P<0.05;**与对照组相比,差异有统计学意义,P<0.01
1
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2
任成山,白 莉,钱桂生. 慢性阻塞性肺疾病合并肺癌临床特征及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(2): 137-142.
3
赵邱煜,信 涛. 非小细胞肺癌脑膜转移治疗的研究进展[J]. 医学综述,2021, 27(02):303-307.
4
Hoffman PC, Mauer AM, Vokes EE. Lung cancer[J]. Lancet, 2000, 355(9202): 479-85.
5
Yoder LH. Lung cancer epidemiology[J]. Medsurg Nurs, 2006, 15(3): 171-174.
6
Chen W, Zheng R, Zeng H, et al. Epidemiology of lung cancer in China[J]. Thorac Cancer, 2015, 6(2): 209-15.
7
Keshamouni V, Arenberg D, Kalemkerian G. Lung Cancer Metastasis[M]. 2010.
8
茆春国,邓 波. 肺癌循环肿瘤细胞侵袭转移机制的研究进展[J].中国肺癌杂志,2020, 23(03): 189-195.
9
朱 丽,龚 波. 下调miR-4262抑制肺癌细胞A549转移潜能的机制[J].分子诊断与治疗杂志,2020, 12(10): 1375-1379.
10
郭梦玲,王熙才,陈 艳. 外泌体miRNA与肺癌的发生发展[J]. 中国肿瘤生物治疗杂志,2020, 27(04): 457-462.
11
余昌敏,张 丹,闵 明,等. 外泌体miRNA作为癌症早期诊断标志物的研究进展[J]. 中国免疫学杂志,2020, 36(22): 2786-2790.
12
Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks[J]. Nature cell biology, 2013, 15(6): 546-554.
13
Tang Y, Tang Y, Cheng YS. miR-34a inhibits pancreatic cancer progression through Snail1-mediated epithelial-mesenchymal transition and the Notch signaling pathway[J]. Sci Rep, 2017, 7: 38232.
14
张月朋,陈复辉. miR-34在非小细胞肺癌中研究进展[J]. 中华实用诊断与治疗杂志,2020, 34(06): 643-645.
15
刘 罡,毛重山. miR-34a靶向CD44对肺癌细胞干细胞表型的影响[J]. 中国老年学杂志,2019, 39(10): 2477-2480.
16
王鑫元,国 强,常哲瀚,等. 奥沙利铂通过调控P53、miR-34a抑制胃癌细胞的增殖[J]. 包头医学院学报,2020, 36(10): 67-70+121.
17
Li XJ, Zhang W, Xu K, et al. miR-34a promotes liver fibrosis in patients with chronic hepatitis via mediating Sirt1/p53 signaling pathway[J]. Pathol Res Pract, 2020,216(5): 152876.
18
梁 辰,王 萍,金由辛,等. p53/miR-34a调控网络在肿瘤中的作用[J]. 生命科学,2016, 28(04): 464-469.
19
Zhu H, Chang LL, Yan FJ, et al. AKR1C1 activates STAT3 to promote the metastasis of non-small cell lung cancer[J]. Theranostics, 2018, 8(3): 676-92.
20
Wang AS, Duan GX, Zhao CL, et al. Reduced RKIP expression levels are associated with frequent non-small cell lung cancer metastasis and STAT3 phosphorylation and activation[J]. Oncol Lett, 2017, 13(5): 3039-3045.
21
茹泽园. 肺癌细胞外泌体通过其携带的IL-6介导的STAT3途径诱导肌管萎缩的机制研究[D]. 华中科技大学,2019.
22
Chiang PK, Gordon RK, TAL J, et al. S-Adenosylmethionine and methylation[J]. Faseb J, 1996, 10(4): 471-480.
23
刘绍文. S-腺苷甲硫氨酸(SAMe)对人肝内胆管癌细胞系ICC-9810增殖及迁移能力的影响及作用机制[D]. 皖南医学院,2019.
24
Palmisano WA. DNA methylation markers and early recurrence in stage i lung cancer[J]. N Engl J Med, 2008, 358(11): 1118-1128.
25
孙东峰,田 辉,刘贤锡,等. 鸟氨酸脱羧酶和S-腺苷甲硫氨酸脱羧酶双反义腺病毒对肺癌增殖和侵袭抑制作用的研究[J]. 中华外科杂志,2008, 46(1): 61-64.
26
Torre LA, Siegel RL, Jemal A. Lung cancer statistics[J]. Adv Exp Med Biol, 2016, 893: 1-19.
27
Faure M. Lung cancer in Europe: turning the spotlight on the biggest cancer killer[J]. Eur Respir J, 2016, 47(1): 42-4.
28
范 伟. S-腺苷甲硫氨酸抑制非小细胞性肺癌增殖,侵袭,转移的机制[D]. 广州医科大学,2018.
29
宋伟祥,卢 伟. 腺苷蛋氨酸在肠癌肝转移患者化疗期间的护肝作用[J]. 肿瘤研究与临床,2011(12): 847-848.
30
刘 敏. S-腺苷甲硫氨酸脱羧酶基因表达与大肠癌关系的研究[D]. 山东大学,2006.
31
Zhang F, Wang B, Qin T, et al. IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation[J]. Mol Cell Biochem, 2020, 473(1-2): 1-3.
32
Rokavec M, Oner MG, Li H, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis[J]. J Clin Invest, 2014, 124(4): 1853-1867.
[1] 林建琴, 孔令敏, 陆银凤, 陈勇, 金凤, 叶磊, 陈方梅. PERMA模式对肺癌患者治疗获益感及生活质量的影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 634-638.
[2] 任甜甜, 张玉慧, 祁玲霞, 朱梅冬, 胡佳. 多学科疼痛管理对胸腔镜肺叶切除术后胸痛及应激反应的影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 630-633.
[3] 陶银花, 张红杰, 王亚岚, 陈莲, 张珺. 间歇式气压治疗预防肺癌化疗下肢深静脉血栓的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 605-608.
[4] 张璇, 高杨, 房雅君, 姚艳玲. 保护性机械通气在肺癌胸腔镜肺段切除术中的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 563-567.
[5] 邓世君, 刘晓青, 刘权兴. 信息化管理在肺癌围手术期中的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 466-468.
[6] 殷国青, 曾莉, 贺斌峰, 孙芬芬. Rab26负性调控Nrf2增强肺癌耐药细胞对奥希替尼的敏感性[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 349-355.
[7] 吕欣谕, 李雯, 王娟侠, 邹维, 王艳, 雷杰. 围手术期肺康复训练在胸腔镜肺叶切除术中疗效分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 256-259.
[8] 陈羽霞, 柏佩梅, 芦遥遥. 综合干预对肺癌化疗患者的影响[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 307-309.
[9] 胡航, 陈婷婷, 孙健, 孙云浩, 仇丽敏. 三维重建技术在单操作孔胸腔镜肺段切除术的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 310-312.
[10] 张剑, 卢从华, 李江华, 林采余, 吴迪, 王治国, 聂乃夫, 何勇, 李力. 根据转录组学分析奥希替尼获得性耐药机制的研究[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 195-200.
[11] 张蕊, 李敏, 饶建玲. 肺癌患者癌因性疲乏现状及影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 111-114.
[12] 朱斯悦, 张晓莹, 严玉茹, 陈绯. 介入支气管镜在肺部疾病诊断和治疗中的应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 148-151.
[13] 拉周措毛, 山春玲, 李国蓉, 华毛. 青海西宁地区IPF-LC的病理类型及临床特征分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(01): 25-29.
[14] 任洁, 檀崇斌, 张振华, 刘晨露. PD-1抑制剂对肺癌治疗致甲状腺相关病变的影响因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 784-788.
[15] 顾兴, 张庭秀, 胡绳, 马李杰, 肖贞良. 胸苷激酶1在肺癌性胸腔积液及结核性胸膜炎中的表达[J]. 中华肺部疾病杂志(电子版), 2023, 16(06): 789-792.
阅读次数
全文


摘要